Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability
Boehringer Ingelheim announced today that spesolimab marketed as SPEVIGO received Breakthrough Therapy Designation BTD as an investigational treatment for the prevention of flares in adolescents and adults with generalized pustular psoriasis GPP from the U.S. Food and Drug Administration FDA.
Based on results from the EFFISAYIL 2 trial, which met its primary and key secondary endpoints for the prevention of generalized pustular psoriasis (GPP) flares1,2,3 Designation granted in recognition
L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...
Strategically planning the timing of vaccinations may help to optimize our horse’s protection against infectious diseases.